HCC

>

Latest News

Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC
Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC

June 2nd 2024

With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

Camrelizumab/Rivoceranib Maintains Survival Benefits in uHCC
Camrelizumab/Rivoceranib Maintains Survival Benefits in uHCC

May 30th 2024

Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population

April 28th 2024

Addressing irAEs Limits Interruption or Discontinuation in HCC
Addressing irAEs Limits Interruption or Discontinuation in HCC

April 26th 2024

BMI Affects Survival Probability With Atezolizumab Plus Bevacizumab in HCC
BMI Affects Survival Probability With Atezolizumab Plus Bevacizumab in HCC

April 25th 2024

Video Series
Video Interviews
Podcasts

More News